Anika Therapeutics, Inc. (ANIK)

USD 16.04

(-3.49%)

Market Cap (In USD)

234.91 Million

Revenue (In USD)

166.66 Million

Net Income (In USD)

-82.66 Million

Avg. Volume

52.39 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
15.825-29.12
PE
-
EPS
-
Beta Value
0.857
ISIN
US0352551081
CUSIP
035255108
CIK
898437
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Dr. Cheryl Renee Blanchard Ph.D.
Employee Count
-
Website
https://www.anikatherapeutics.com
Ipo Date
1993-05-03
Details
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.